Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.
Monica Dougherty, PharmD, BCACP
Advertisement
Articles by Monica Dougherty, PharmD, BCACP
New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Vaccine Guidance Is Rapidly Changing—Here's What You Need to Know
2
FDA Approves First OTC Acetaminophen-Naproxen Combination for 12-Hour Pain Relief
3
What Real-World Data Show About Moving Patients From Humira to Biosimilars
4
New Review Offers Framework for Sequencing Disease-Modifying Therapies in MS
5